Comparison
GHRP-6 vs Omega-3 (EPA/DHA)
Side-by-side of GHRP-6 and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
GHRP-6
First-generation hexapeptide ghrelin-receptor agonist. Pioneered the GHS-R1a pathway in the 1980s. Produces the strongest hunger response among GHRPs and a mo.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Effects at a glance
GHRP-6
- •First-generation hexapeptide ghrelin-receptor agonist; foundational to the GHRP class
- •Strongest appetite stimulation of any synthetic GHRP at equivalent GH doses
- •Produces measurable cortisol and prolactin rise alongside the GH pulse
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Largely superseded by ipamorelin (cleaner profile) and GHRP-2 (stronger pulse) for body-composition use
- •Banned by WADA under S2; detection methods validated in accredited labs
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Side-by-side
| Attribute | GHRP-6 | Omega-3 (EPA/DHA) |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Growth Hormone Releasing Peptide 6, SKF-110679, Histidyl-D-Tryptophyl-Alanyl-Tryptophyl-D-Phenylalanyl-Lysinamide | fish oil, EPA, DHA, marine omega-3 |
| Half-life (hr) ↗ | 0.5 | 48 |
| Typical dose (mg) ↗ | 0.1 | 2000 |
| Dosing frequency | 2-3x daily | 1 to 2 times daily with food |
| Routes | subcutaneous, intravenous | oral |
| Onset (hr) | 0.25 | 4 |
| Peak (hr) | 0.5 | 12 |
| Molecular weight | 872.44 | 302.45 |
| Molecular formula | C46H56N12O6 | C20H30O2 (EPA); C22H32O2 (DHA) |
| Mechanism | Hexapeptide agonist of GHS-R1a (ghrelin receptor). Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs, with strong central NPY/AgRP appetite signaling and modest cortisol and prolactin release. | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | Not scheduled |
| Pregnancy | Insufficient data; not recommended | Recommended at 200 to 600 mg DHA/day for fetal development |
| CAS | 87616-84-0 | 10417-94-4 |
| PubChem CID | 9919072 | 446284 |
| Wikidata | Q5519921 | Q207688 |
Safety profile
GHRP-6
Common side effects
- intense hunger
- water retention
- vivid dreams
- head pressure or flushing
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin sensitivity
Interactions
- CJC-1295: synergistic GH release; commonly co-administered(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. GHRP-6 is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick GHRP-6.
- → If your priority is appetite regulation, pick GHRP-6.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for GHRP-6 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between GHRP-6 and Omega-3 (EPA/DHA)?
GHRP-6 and Omega-3 (EPA/DHA) differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, GHRP-6 or Omega-3 (EPA/DHA)?
GHRP-6 half-life is 0.5 hours; Omega-3 (EPA/DHA) half-life is 48 hours.
Can you stack GHRP-6 with Omega-3 (EPA/DHA)?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper